J
Janice Canvin
Researcher at Novartis
Publications - 35
Citations - 3146
Janice Canvin is an academic researcher from Novartis. The author has contributed to research in topics: Omalizumab & Placebo. The author has an hindex of 18, co-authored 35 publications receiving 2829 citations. Previous affiliations of Janice Canvin include University of Manitoba & Glasgow Royal Infirmary.
Papers
More filters
Journal ArticleDOI
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Marcus Maurer,Karin Rosén,Hsin-Ju Hsieh,Sarbjit S. Saini,Clive Grattan,Ana Giménez-Arnau,Sunil Agarwal,Ramona Doyle,Janice Canvin,Allen P. Kaplan,Thomas B. Casale +10 more
TL;DR: Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamine therapy (licensed doses).
Journal ArticleDOI
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Allen P. Kaplan,Dennis K. Ledford,Mark Ashby,Janice Canvin,James L. Zazzali,Edward Conner,Joachim Veith,Nikhil Kamath,Petra Staubach,Thilo Jakob,Robert G Stirling,Piotr Kuna,William E. Berger,Marcus Maurer,Karin Rosén +14 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent chronic idiopathic urticaria/chronic spontaneous urticria (CIU/CSU) despite treatment with H 1 -antihistamines at up to 4 times the approved dose plus H 2 -antiHistamines, leukotriene receptor antagonists, or both.
Iconographies supplémentaires de l'article : Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Allen P. Kaplan,Dennis K. Ledford,Mark Ashby,Janice Canvin,James L. Zazzali,Edward Conner,Joachim Veith,Nikhil Kamath,Petra Staubach,Thilo Jakob,Robert G Stirling,Piotr Kuna,William E. Berger,Marcus Maurer,Karin Rosén +14 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent chronic idiopathic urticaria/chronic spontaneous urticria (CIU/CSU) despite treatment with H1-antihistamines, leukotriene receptor antagonists, or both.
Journal ArticleDOI
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
Sarbjit S. Saini,Carsten Bindslev-Jensen,Marcus Maurer,Jean-Jacques Grob,Emel Bülbül Başkan,Mary S. Bradley,Janice Canvin,Abdelkader Rahmaoui,Panayiotis Georgiou,Oral Alpan,Sheldon Spector,Karin Rosén +11 more
TL;DR: Omalizumab 300 mg administered subcutaneously every 4 weeks reduced weekly ISS and other symptom scores versus placebo in CIU/CSU patients who remained symptomatic despite treatment with approved doses of H1 antihistamines.
Journal ArticleDOI
Omalizumab in Asthma: An Update on Recent Developments
Marc Humbert,William W. Busse,Nicola A. Hanania,Philip J. Lowe,Janice Canvin,Veit J. Erpenbeck,Stephen T. Holgate +6 more
TL;DR: Results from recent pooled data from randomized clinical trials and from a large prospective cohort study provide reassurance about the long-term safety of omalizumab.